Diagnostic anchoring in metastatic adenocarcinoma –⁠ Was the turning point too late?

Czech version

Authors: Dr. Muhammad Hafiz, Spp
Authors‘ workplace: Lung Cancer Center, MRCCC Siloam Hospitals Semanggi, Jakarta, Indonesia ¹; Department of Pulmonology and Respiratory Medicine, Budhi Asih General Hospital, Jakarta, Indonesia ²
Published in: Klin Onkol 2026; 39(5): 378
Category: Letter to Editor

Sources

1. Pešek M, Drösslerová M, Vaněček T et al. FGFR2 fusion as the key to targeted therapy –⁠ a case report with a diagnostic turning point. Klin Onkol 2026; 39 (4): 287–293. doi: 10.48095/ccko2026287. 

2. Turner BM, Cagle PT, Sainz IM et al. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma. Arch Pathol Lab Med 2012; 136 (2):   163–171. doi: 10.5858/arpa.2011-0320-OA. 

3. Ordóñez NG. Value of thyroid transcription factor-1 immunostaining in tumor diagnosis: a review and update. Appl Immunohistochem Mol Morphol 2012; 20 (5): 429–444. doi: 10.1097/PAI.0b013e31825439bc. 

4. Compérat E, Zhang F, Perrotin C et al. Variable sensitivity and specificity of TTF-1 antibodies in lung metastatic adenocarcinoma of colorectal origin. Mod Pathol 2005; 18 (10): 1371–1376. doi: 10.1038/modpathol.3800422. 